Recruiting NCT07627074
Weight Loss in Adults Using Semaglutide (Real-world Study)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Semaglutide.
- Who it may be relevant to
- Registry conditions: Overweight, Obesity. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study
Overview
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Interventions
- Drug Semaglutide
This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.
Primary outcome measures
- Change in body weight [Time frame: From index date (day 0) to week 68 (day 476)]
- Change in body weight [Time frame: From index date (day 0) to week 68 (day 476)]
- Proportion of individuals achieving a clinically meaningful weight loss [Time frame: From index date (day 0) to week 68 (day 476)]
Eligibility criteria
Inclusion criteria
- Initiation of semaglutide for weight management during the study period.
- Age more than or equal to (≥) 18 at treatment initiation
- Baseline body mass index (BMI) ≥27 and less than (<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2.
- Other inclusion criteria as defined in the protocol are applicable.
Exclusion criteria
- Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
- Bariatric surgery at baseline.
- Diabetes at baseline.
- Pregnancy at baseline.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Novo Nordisk Investigational Site — Seattle
United Kingdom · 1 center
- Novo Nordisk Investigational Site — London
Identifiers
NCT: NCT07627074 · NN9536-8874 · U1111-1338-2016